Show simple item record

dc.contributor.authorPintér, Dávid
dc.contributor.authorMartinez-Martin, Pablo 
dc.contributor.authorJanszky, József
dc.contributor.authorKovács, Norbert
dc.date.accessioned2020-03-18T09:48:39Z
dc.date.available2020-03-18T09:48:39Z
dc.date.issued2019
dc.identifier.citationParkinsons Dis. 2019 Sep 10;2019:1412984.es_ES
dc.identifier.issn2090-8083es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9273
dc.description.abstractBackground: The Parkinson's Disease Composite Scale (PDCS) is a recently developed easy-to-use tool enabling a timely but comprehensive assessment of Parkinson's disease (PD)-related symptoms. Although the PDCS has been extensively validated, its responsiveness to acute levodopa challenge has not been demonstrated yet. Objective: To investigate the correlation between changes in the motor examination part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the PDCS motor scores during acute levodopa challenge and calculate a cutoff range on the PDCS indicating clinically relevant improvement. Methods: A consecutive series of 100 patients with parkinsonism were assessed using the motor examination sections of the MDS-UPDRS and the PDCS at least 12 hours after the last levodopa dose and after the administration of a single dose of a suprathreshold immediate formulation of levodopa/benserazide reaching the "best ON." Results. There was a high correlation between changes in the MDS-UPDRS and the PDCS motor scores (Spearman's rho = 0.73, p < 0.001). Receiver operating characteristic analysis revealed that a 14.6%-18.5% improvement in the PDCS motor scores corresponds to a 20-30% improvement in the MDS-UPDRS motor examination. Conclusions: The PDCS can reliably and adequately respond to an acute levodopa challenge. Any improvements in PDCS motor scores exceeding the 14.6-18.5% threshold could represent a clinically relevant response to levodopa.es_ES
dc.description.sponsorshipThis study was supported by the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002) and NKFIH (EFOP-3.6.2-16-2017-00008, SNN125143, and ÚNKP-17-4-I.-PTE-311) (government-based funds). Our research was partly financed by the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the 5th thematic program of the University of Pécs, Hungary (20765/3/2018/FEKUSTRAT). The authors would like to thank Éva Balázs and Katalin Takács, our Parkinson’s nurses, for their assistance in study-related examinations.es_ES
dc.language.isoenges_ES
dc.publisherHindawi es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleThe Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challengees_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID31583072es_ES
dc.format.volume2019es_ES
dc.format.page1412984es_ES
dc.identifier.doi10.1155/2019/1412984es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1155/2019/1412984es_ES
dc.identifier.journalParkinson's diseasees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDInfo:eu-repo/grantAgreement/2017-1.2.1-NKP-2017-00002es_ES
dc.relation.projectIDInfo:eu-repo/grantAgreement/EFOP-3.6.2-16-2017-00008es_ES
dc.relation.projectIDInfo:eu-repo/grantAgreement/SNN125143es_ES
dc.relation.projectIDInfo:eu-repo/grantAgreement/ÚNKP-17-4-I.-PTE-311es_ES
dc.relation.projectIDInfo:eu-repo/grantAgreement/20765/3/2018/FEKUSTRATes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional